Document Detail

Cancer immunoprevention.
MedLine Citation:
PMID:  16555976     Owner:  NLM     Status:  MEDLINE    
Immunoprevention is a fresh approach to cancer prevention based on the stimulation of the immune system before tumor onset. Immunoprevention was effective in various models of carcinogen-induced or autochthonous tumor progression. Vaccines made of cells or DNA plasmids combined with appropriate adjuvants completely blocked mammary carcinogenesis in HER-2/neu transgenic mice. At variance with cancer immunotherapy, the mediators of immunoprevention are antibodies and T-cell-derived cytokines, rather than cytotoxic T-cells. Immunopreventive approaches and chemoprevention with tamoxifen or cyclooxygenase-2 inhibitors can be combined advantageously. The success obtained in preclinical studies suggests that cancer immunoprevention should progress to clinical testing.
Pier-Luigi Lollini; Carla De Giovanni; Tania Pannellini; Federica Cavallo; Guido Forni; Patrizia Nanni
Related Documents :
18081536 - Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer.
23917546 - Management of psychiatric inpatients with advanced cancer: a pilot study.
25139166 - Mean sojourn time of preclinical gastric cancer in korean men: a retrospective observat...
16978826 - Analyses and perspectives in cancer immunotherapy.
15562946 - Coverage and quality of oral cancer information in selected popular press: may 1998 to ...
19805306 - Apkclambda/iota promotes growth of prostate cancer cells in an autocrine manner through...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Future oncology (London, England)     Volume:  1     ISSN:  1479-6694     ISO Abbreviation:  -     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2006-03-24     Completed Date:  2006-05-04     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  101256629     Medline TA:  Future Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  57-66     Citation Subset:  IM    
Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I-40126 Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use
Anticarcinogenic Agents / therapeutic use
Cancer Vaccines / immunology
Immune System / physiology
Interleukin-12 / genetics
Mice, Transgenic
Neoplasms / immunology*,  prevention & control*
Precancerous Conditions / immunology,  prevention & control
Receptor, erbB-2 / immunology*,  physiology
T-Lymphocytes, Cytotoxic / immunology
Vaccines, DNA / immunology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Anticarcinogenic Agents; 0/Cancer Vaccines; 0/Vaccines, DNA; 187348-17-0/Interleukin-12; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biomarkers of genetic susceptibility to cancer: applications to epidemiological studies.
Next Document:  Role of IkappaB kinase in tumorigenesis.